MVision AI and Institut de Cancérologie de Lorraine (ICL, Nancy) announce the first installation of unique Guide and Verify solutions for cancer treatment in France

HELSINKI, Finland – November 24, 2023

Institut de Cancérologie de Lorraine (ICL) in Nancy (France) has been a MVision AI customer since the installation of Contour+ in January 2023. This year, the values of using Guideline-Based AI Segmentation in daily practice have been prominently featured in several French media outlets [1], thanks to the efforts of Dr. Jean Christophe Faivre, head of the radiation oncology department. In fact, France Bleu even compared the results of using Contour+ to a small revolution in radiotherapy treatment.

Clinicians have particularly emphasized the accuracy and time-saving benefits, which allow for more time to be allocated to patient care and target identification.

The accuracy of organ-at-risk (OAR) contouring can significantly influence cancer treatment planning. Contour+, powered by AI, not only assists us in contouring these critical organs to protect them but also enables us to achieve much greater precision while saving time“, says Dr. Jean Christophe Faivre.

Today we manually outline ten to fifteen patients a day, with Contour+, the medical team can easily handle twenty to thirty. This allows us to create much finer and more personalized irradiation plans, ultimately benefiting the patients. The tool is also invaluable in mitigating the current shortage of healthcare professionals in French hospitals. Our team eagerly anticipates future developments with AI“.

ICL is upfront in using artificial intelligence for cancer patients care and we are proud to reach the next steps in the near future by providing MVision AI Guide & Verify web workspaces designed to support clinical teams in the adoption of responsible AI with contour comparison and standardization towards guidelines.

About Institut de Cancérologie de Lorraine – Alexis Vautrin

The Institute of Cancer Research, along with its affiliation to Unicancer through Alexis Vautrin, plays a vital role as the central hub for cancer control in the Lorraine region. ICL is dedicated to delivering both standard and highly specialized care to cancer patients. Established in 1924, the Institut de Cancerologie de Lorraine holds a prominent position as a reference institution, providing tailored care pathways for patients and ensuring optimal care through the latest technological advancements. In 2022, the ICL achieved certification by the High Health Authority (HAS) at the “High Quality of Care” level, underscoring its commitment to excellence.

Institut de Cancérologie de Lorraine – ICL Linkedin page

About MVision AI

MVision AI is your dedicated partner in healthcare innovation. Our team comprises experienced Radiation Oncologists, Radiation Therapists, Medical Physicists and Clinical Scientists with a strong commitment to transforming the landscape of cancer care through the utilization of state-of-the-art AI technology. Our GBS™ Guideline-Based segmentation solution, powered by AI, is designed to streamline treatment planning, enabling clinicians to focus on personalized treatment plans that consider each patient’s distinct anatomy and medical history. This approach can potentially yield enhanced treatment outcomes, reduced side effects, and shorter treatment durations. The GBS™ suite encompasses three groundbreaking products for radiation therapy: the extensively updated Contour+ [2], and the recently launched Guide and Verify [3].

MVision AI Linkedin page

MVision AI Media Kit


[1] – L’intelligence artificielle au service des patients atteints de cancer à Nancy – Nancy : l’intelligence artificielle au service des patients atteints de cancers

France 3 Grand Est – L’Intelligence Artificielle contre le cancer à l’institut de cancérologie de Lorraine

[2] – Press Release: MVision AI launches Contour+ auto-contouring to facilitate standardization and shorten time to treatment for cancer radiotherapy

[3] – Press Release: MVision AI is proud to announce the launch of the world’s first comprehensive Guideline-Based Segmentation (GBS™) solution for responsible radiation therapy contouring

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts


World Kidney Cancer Day 2024: “Listen”

World Kidney Cancer Day is observed every year on the second Thursday of June. “Listening” is this year’s theme, which refers to the benefits of shared decision making, patient’s empowerment to seek a second opinion and creating awareness around misinformation and how to check if sources are reliable (1). More…



MVision AI Appoints Antti Pirskanen as New Chief Financial Officer

Helsinki, Finland – June 14, 2024 – MVision AI, a pioneering company in the development of innovative AI solutions for radiation oncology is pleased to announce the appointment of Antti Pirskanen as its new Chief Financial Officer (CFO). Antti will assume his responsibilities immediately, bringing extensive expertise in financial management…

Press Releases


MVision AI Receives MFDS Approval and Market Authorization for South Korea

HELSINKI, Finland – June 14, 2024 MVision AI is pleased to announce that our application for MVision AI Segmentation (Contour+) in South Korea has been accepted by the Ministry of Food and Drug Safety (MFDS) under the “Image Segmentation Application Software” for image analysis algorithms to be used in radiation…

Press Releases